Publications de Elise Hélène Dumas

Trusting emulated trials: when real-world data predict real-world results in ovarian cancer

2025

Explaining the Relationships Between Age, Endocrine Therapy Persistence, and Risk of Recurrence in Hormone Receptor–Positive Early Breast Cancer: A Nationwide Cohort Study

Mats Julius Stensrud, Elise Hélène Dumas

Young age is associated with increased risk of recurrence in hormone receptor (HR)–positive early-stage breast cancer (eBC). Lack of adherence to endocrine therapy (ET) is a potential reason for the lower survival proportions observed in younger patients, ...

American Society of Clinical Oncology (ASCO)2025

The impact of fat graft reconstructive surgery on prognosis in young women with breast cancer: a study from the French insurance databases

Elise Hélène Dumas

Introduction: Fat graft (FG) is widely used in breast reconstructive surgery (RS) following mastectomy or lumpectomy for breast cancer (BC); however, concerns persist about its oncological safety. This study evaluates the impact of FG reconstruction compar ...

2025

Association Between Daily Timing of Everolimus and Survival in High‐Risk HR+/HER2− Early Breast Cancer: A Sub‐Analysis of the UCBG‐UNIRAD Trial

Elise Hélène Dumas

In the UNIRAD phase III trial, evening intake of tamoxifen was previously associated with improved disease‐free survival (DFS), while no timing effect was observed for aromatase inhibitors. This sub‐study evaluated whether the timing of everolimus intake a ...

Wiley2025

How hazard ratios can mislead and why it matters in practice

Mats Julius Stensrud, Elise Hélène Dumas

Hazard ratios are routinely reported as effect measures in clinical trials and observational studies. However, many methodological works have raised concerns about the interpretation of hazard ratios as causal effects. These concerns are often related to t ...

Springer Science and Business Media LLC2025

Comedications Associated with Immune-related Adverse Events From Immune-checkpoint Inhibitors

Elise Hélène Dumas

Immune-checkpoint inhibitors (ICI) have revolutionized cancer treatment but are responsible for various immune-related adverse events (irAE). The impact of non-anticancer medications (comedications) on irAE occurrence remains largely unexplored. The object ...

WILEY2025

From Prediction to Prescription: Machine Learning and Causal Inference for the Heterogeneous Treatment Effect

Elise Hélène Dumas

The increasing accumulation of medical data brings the hope of data-driven medical decision-making, but data's increasing complexity—as text or images in electronic health records—calls for complex models, such as machine learning. Here, we review how mach ...

Annual Reviews2025

BCR::ABL1 Tyrosine Kinase Inhibitors During Pregnancy, a Disproportionality Analysis of Vigibase

Elise Hélène Dumas

Tyrosine kinase inhibitors (TKIs) targeting BCR::ABL1 have greatly improved the survival of patients with chronic myeloid leukemia (CML), and their teratogenicity appears as an important factor for individuals of childbearing potential. This study aims to ...

Wiley2025

Survival outcomes of primary vs interval cytoreductive surgery for International Federation of Gynecology and Obstetrics stage IV ovarian cancer: a nationwide population-based target trial emulation

Elise Hélène Dumas

BACKGROUND: The effect of primary cytoreductive surgery vs interval cytoreductive surgery on International Federation of Gynecology and Obstetrics stage IV ovarian cancer outcomes remains uncertain and may vary depending on the stage and the location of ex ...

MOSBY-ELSEVIER2025

Causality: fundamental principles and tools

Elise Hélène Dumas

This chapter aims to provide a gentle introduction to Causal Learning (CL), and motivation for its application to medical image analysis, seeking for more robustness against data and domain drifts, and a reliable tool to answer counterfactual questions and ...

Academic Press2025